anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Pregabalin
Trial phase: Phase 3
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 183
Group description: Pregabalin 75 milligram (mg) capsule orally twice daily up to Week 1, followed by pregabalin 150 mg capsule orally twice daily up to Week 2, then pregabalin 225 mg capsule orally twice daily up to Week 3, participants who had inadequate pain control and had tolerated pregabalin 225 mg twice daily received pregabalin 300 mg capsule orally twice daily up to Week 4, during 4-week titration (adjustment) phase. Pregabalin capsule 75 mg, 150 mg, 225 mg, or 300 mg orally twice daily (as per tolerability in titration phase) from Week 5 to Week 16, during 12-week maintenance phase. Participants underwent an end-of-study medication taper over a 1-week period.
Eligibility criteria:
Inclusion Criteria:

Men and women, ages of 18 or greater
Documented evidence of HIV-1 infection
Documented diagnosis of HIV-associated Distal Symmetrical Polyneuropathy (DSP) with subjective sensory symptom of pain
Pain starts in the feet

Exclusion Criteria:

Subject has untreated vitamin B12 deficiency (serum B12 level <200 pg/ml) or if treated B12 deficiency -treatment is less than 6 months of B12 supplementation (injection or intranasal B12) prior to screening
Diabetes mellitus requiring regular medical treatment (other than diet and exercise) or HbA1C >6.9
Subjects with peripheral neuropathic pain that is not associated with HIV infection; including subjects with conditions such as: Post Herpetic Neuralgia (PHN), Diabetic Peripheral Neuropathy (DPN), familial neuropathies; compression related neuropathy, radicular pain, other infection related neuropathies (eg, leprosy); neuropathy related to: metabolic abnormalities; nutritional factors; vascular insults; inflammation; autoimmune disease; and malignancy
Intervention: Flurbiprofen
Trial phase: Phase 3
ATC code: M01AE09 | M02AA19 | M02AA29 | R02AX01 | S01BC04
SMILES: CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 102
Group description: Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
Eligibility criteria:
Inclusion Criteria:

The patient has a complaint of sore throat.
If the patient is a female of childbearing potential, she has been using effective contraception since the last date of menses and is not breast-feeding or lactating.
If the patient is a female of childbearing potential, the patient must have a negative urine pregnancy.
The patient has provided written informed consent prior to any study-related procedures.

Exclusion Criteria:

The patient has a history of an upper gastrointestinal ulcer within the past 60 days, is currently experiencing clinically significant upper gastrointestinal complaints, or is currently taking medication regularly (≥ three times in the previous week).
The patient has a history of any hepatic disease or renal dysfunction.
The patient has a history of chronic analgesic use (≥ three times per week over the prior four weeks). (Patients on low-dose aspirin therapy may be allowed in the study per investigator's clinical decision.)
Intervention: 3-Heptadecylcatechol
Trial phase: Phase 3
SMILES: CCCCCCCCCCCCCCCCCc1cccc(O)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 112
Group description: HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
Eligibility criteria:
Inclusion Criteria:

Male and female patients
Aged 18 - 75 years
Chronic low-back pain lasting at least for 6 months
Hanover functional ability questionnaire (FFbH-R) score less than 70%

At least one of the following diagnoses:

Chronic lumbar ischialgia with or without radicular radiation
Chronic degenerative lumbar syndrome
Spondylarthrosis
Chronic facet syndrome
Lumbago with protrusion of the intervertebral disc
Lumbar radiculopathy
Lumbar and other intervertebral disc impairments with radiculopathy
Back pain at different locations of the spine
Written, informed consent

Exclusion Criteria:

Participation in another clinical trial/GCP-trial within 30 days prior to screening
Participation in this trial in an earlier time
Treatment with lymphdiaral basistropfen within 3 month prior to enrolment
Pregnancy and lactation
Non-compliance
Incapability to understand the sense of the study
Abuse of analgesics, opiates or other drugs
Chronic pain that are as strong as or even stronger than the pain caused by the low-back and that need to be treated with analgesics
Malign diseases
Pathological neurological states
Epilepsy
Operation of the spine within 3 month prior to enrolment
Fractures of the spine
Bechterew's disease
Alcohol abuse
Consuming diseases
Cachexia
Palsy of the legs or anal sphincter due to acute impairment of the intervertebral disc
Catheterisation or CT-controlled intra-articular injection in the lumbar region
Hypersensitivity against one of the ingredients or excipients of the study drugs or against composite plants in general
Systemic, progressive diseases like tuberculosis, leucosis, collagenosis, multiple sclerosis, acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, or other auto-immune diseases
Intervention: Sugammadex
Trial phase: Phase 3
ATC code: V03AB35
SMILES: O=C(O)CCSCC1OC2OC3C(CSCCC(=O)O)OC(OC4C(CSCCC(=O)O)OC(OC5C(CSCCC(=O)O)OC(OC6C(CSCCC(=O)O)OC(OC7C(CSCCC(=O)O)OC(OC8C(CSCCC(=O)O)OC(OC9C(CSCCC(=O)O)OC(OC1C(O)C2O)C(O)C9O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: sugammadex 2 mg/kg
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists Class 1 or 2 or 3
>=18 years of age and of either sex
scheduled for elective surgical procedure under general anesthesia requiring the use of rocuronium for endotracheal intubation and/or maintenance of neuromuscular blockade in a supine position allowing neuromuscular transmission monitoring and requiring reversal of neuromuscular blockade
Korean descent born in Korea, never emigrated out of Korea, and have a Korean home address

Exclusion Criteria:

expected difficult intubation due to anatomic malformations
expected transfer to intensive care unit after surgery
neuromuscular disorders affecting neuromuscular blockade
significant hepatic or renal dysfunction
require use of pneumatic tourniquet during surgery
(family) history of malignant hyperthermia
allergy to cyclodextrins (including sugammadex) or other medication(s) used during general anesthesia; use of toremifene or fusidic acid within 24 hours of study drug administration; contraindication to use of neostigmine or glycopyrrolate
Intervention: Neostigmine
Trial phase: Phase 3
ATC code: N07AA01 | N07AA51 | S01EB06
SMILES: CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: neostigmine 50 mcg/kg
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists Class 1 or 2 or 3
>=18 years of age and of either sex
scheduled for elective surgical procedure under general anesthesia requiring the use of rocuronium for endotracheal intubation and/or maintenance of neuromuscular blockade in a supine position allowing neuromuscular transmission monitoring and requiring reversal of neuromuscular blockade
Korean descent born in Korea, never emigrated out of Korea, and have a Korean home address

Exclusion Criteria:

expected difficult intubation due to anatomic malformations
expected transfer to intensive care unit after surgery
neuromuscular disorders affecting neuromuscular blockade
significant hepatic or renal dysfunction
require use of pneumatic tourniquet during surgery
(family) history of malignant hyperthermia
allergy to cyclodextrins (including sugammadex) or other medication(s) used during general anesthesia; use of toremifene or fusidic acid within 24 hours of study drug administration; contraindication to use of neostigmine or glycopyrrolate
Intervention: Risperidone
Trial phase: Phase 4
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 133
Group description: Subjects with at least 6 months exposure to risperidone within 24 months prior to enrollment
Eligibility criteria:
Inclusion Criteria:

One or both parents (according to local regulations) or a guardian must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study (If appropriate according to local regulations, the patient must also assent)
Treated for schizophrenia, bipolar mania, autistic disorder, or conduct and other disruptive behavior disorders
Had at least 6 months of exposure for an atypical antipsychotic drug within 24 months before the study visit (patients may or may not be taking the atypical antipsychotics at the time of actual enrollment, eligible patients can have exposure to multiple atypical antipsychotics, however, they cannot concomitantly be exposed to more than 1 atypical antipsychotic for a period of greater than 30 days)
Had medical records or automated data available for at least 1 year prior to the start of exposure
Height and weight were recorded at least once within 1 year before the start of exposure, and if available at any time points after the start of exposure in the medical records or electronic databases (not mandatory)

Exclusion Criteria:

Have at least 1 medical record, at any time before the start of exposure, consistent with malignancy (other than non-melanoma skin cancer), pregnancy, or a developmental delay or abnormality associated with growth or sexual maturation delays not related to the specified indications
Had exposure to prolactin elevating medications other than atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs)
Had exposure to Paliperidone
Cannot comply with study procedures
Intervention: HYDROXYPROGESTERONE CAPROATE
Trial phase: Phase 1 | Phase 2
ATC code: G03DA03
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(OC(=O)CCCCC)C(C)=O
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation

17-Hydroxyprogesterone Caproate: Weekly injections of 17-hydroxyprogesterone caproate.
Eligibility criteria:
Inclusion Criteria:

18yr of age
Singleton pregnancy
PPROM confirmed on clinical exam
GA between 24+0 and 33+5 wk
Ability to understand consent in either English or Spanish

Exclusion Criteria:

Contraindication to ongoing pregnancy including:

Evidence of active infection
Evidence of significant placental abruption
IUFD diagnosed at the time of P-PROM diagnosis
Major fetal malformation
Maternal allergy to progesterone or placebo drug components
Current use of progesterone at the time of P-PROM
Multiple Gestations
Inability to understand consent in either English or Spanish
Intervention: Miltefosine
Trial phase: Phase 2
ATC code: P01CX04
SMILES: CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Miltefosine: 2.5 mg/kg/day for 28 days
Eligibility criteria:
Inclusion Criteria:

Is the subject a male or female at least 18 years of age?
Does the subject weigh at least 30 kg?
Does the subject have a diagnosis of mucosal leishmaniasis or cutaneous leishmaniasis in at least one lesion by at least one of the following methods: 1) positive culture for promastigotes of lesion material, 2) microscopic identification of amastigotes in stained lesion tissue, 3) Polymerase chain reaction of lesion material?
In the opinion of the investigator, is the subject capable of understanding and complying with the protocol?
If female and of child-bearing potential, did the subject have a negative pregnancy test during screening and agree to use an acceptable method of birth control during the treatment phase and for 6 months after treatment is completed?
Has the patient signed informed consent?

Exclusion Criteria:

Is the subject a female who is breast-feeding?

Does the subject have a clinically significant medical disorder?

Thrombocyte count <100 x 10e9/L
Leukocyte count <3 x 10e9/L
Haemoglobin <10 g/100 mL
Aspartate transaminiase (ASAT), alanine transaminase (ALAT) >2 times upper limit of normal range
Bilirubin >1.5 times upper limit of normal range
Serum creatinine >1.5 times upper limit of normal range
Major surgery within last 2 weeks
Any non-compensated or uncontrolled condition
In the last 4 weeks up to the present, has the subject received other treatment for leishmaniasis, including any medication with pentavalent antimony; amphotericin B, paromomycin, or imidazoles?
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.
Eligibility criteria:
Inclusion Criteria:

Female patients undergoing outpatient laparoscopic gynecologic surgery
ASA PS I and II
Age between 18 and 64 years
Fluent in English

Exclusion Criteria:

History of recent respiratory tract infection
Pregnancy, breastfeeding
Current treatment with analgesics
Current use of corticosteroids
Anticipated difficult intubation
Risk factors for post-operative aspiration
Intervention: Ramipril
Trial phase: Phase 2 | Phase 3
ATC code: C09AA05 | C09BA05 | C09BB05 | C09BB07 | C09BX03 | C09BX05 | C10BX04 | C10BX06 | C10BX17 | C10BX18
SMILES: [H][C@@]12CCC[C@]1([H])N(C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC)[C@H](C(=O)O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
Eligibility criteria:
Inclusion Criteria:

21 years old or older

MI documented by increase in troponin > 0.78 ng/ml or CKMB ≥ 3% of total CK

Patients who have Type-2 diabetes defined by any one of the following:

Confirmed (i.e., two or more readings) fasting blood glucose >126mg/dl; or
Random glucose ≥200mg/dl; or
2 hour glucose ≥200mg/dl following 75g of glucose; or
Current treatment with diet or oral agents directed at the control of hyperglycemia either alone or in combination with insulin; or
Current treatment with insulin with no prior history of diabetic ketoacidosis.

Exclusion Criteria:

Type-1 diabetes.
Class III or IV heart failure.
Cardiomyopathy (including hypertrophic and amyloidosis).
Congenital or pericardial diseases.
Intolerance to either ACE inhibitor, AT1-RB or allopurinol.
Renal failure with creatinine > 2.5 mg/dl.
Renal artery stenosis.
Severe comorbidity such as liver disease or malignancy.
Pregnancy (negative pregnancy test and effective contraceptive methods are required prior to enrollment of females of childbearing potential (not post-menopausal or surgically sterilized).
Chronic steroid use.
Unable to understand or cooperate with protocol requirements.
Severe claustrophobia.
Presence of a pacemaker or non-removable hearing aid.
Presence of metal clips in the body.
Intervention: Memantine
Trial phase: Phase 2 | Phase 3
ATC code: N06DA52 | N06DA53 | N06DX01
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.

Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 30 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week.

Memantine: 30mg/day Memantine orally everyday for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Men and women between 18-25 years old
Opioid dependence as evidenced by signs of opiate withdrawal, self-reported history of opioid dependence for a consecutive 12 month period and positive urine for opioids

Exclusion Criteria:

Current diagnosis of other drug or alcohol dependence (other than opiates, cannabis or tobacco)
Serious medical illness (e.g. major cardiovascular, renal, endocrine, hepatic disorder)
Current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder and participants with suicidal or homicidal thoughts
Women who are pregnant, nursing or refuse to use a reliable form of birth control or refuse monthly pregnancy testing
Screening liver function tests (SGOT or SGPT) greater than 3 times normal
Intervention: Memantine
Trial phase: Phase 2 | Phase 3
ATC code: N06DA52 | N06DA53 | N06DX01
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.

Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 15 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week.

Memantine: 15 mg/day Memantine orally everyday for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Men and women between 18-25 years old
Opioid dependence as evidenced by signs of opiate withdrawal, self-reported history of opioid dependence for a consecutive 12 month period and positive urine for opioids

Exclusion Criteria:

Current diagnosis of other drug or alcohol dependence (other than opiates, cannabis or tobacco)
Serious medical illness (e.g. major cardiovascular, renal, endocrine, hepatic disorder)
Current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder and participants with suicidal or homicidal thoughts
Women who are pregnant, nursing or refuse to use a reliable form of birth control or refuse monthly pregnancy testing
Screening liver function tests (SGOT or SGPT) greater than 3 times normal
Intervention: Ferumoxides
Trial phase: Phase 2
SMILES: [Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Participants received an IV injection of ferumoxytol (510 mg, 17 mL) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 g.
Eligibility criteria:
Inclusion Criteria:

Key Inclusion Criteria include:

Males and females ≥18 years of age
An estimated glomerular filtration rate <60 mL/minute or a diagnosis of CKD (such as nephropathy, nephritis)
Hemoglobin <11.0 g/deciliter (dL)
Transferrin saturation <30%
Hemodialysis participants on maintenance dialysis for at least 3 months prior to screening and currently receiving dialysis 3 times per week
Female participants of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of the study

Exclusion Criteria:

Key Exclusion Criteria include:

History of allergy to IV iron
Allergy to 2 or more classes of drugs
Female participants who are pregnant or intend to become pregnant, breastfeeding, within 3 months postpartum, or have a positive serum or urine pregnancy test
Hemoglobin ≤7.0 g/dL
Received another investigational agent within 4 weeks prior to screening, or planned receipt of an unspecified investigational agent during the study period
Known causes of anemia other than iron deficiency (such as hemolysis and vitamin B12 or folate deficiency)
Intervention: Gabapentin
Trial phase: Phase 3
ATC code: N02BF01 | N03AX12
SMILES: NCC1(CC(=O)O)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)

Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy

Gabapentin 300mg:

Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily
Eligibility criteria:
Inclusion Criteria:

First course of chemotherapy ( cisplatin or doxorubicin at a dose of at least 50mg per square meter)
Written informed consent must be obtained before initiating the protocol procedures

Exclusion Criteria:

ECOG 3
Nausea and vomiting within the past 1 day
Gastrointestinal obstruction
Concurrent use of opioid
Patients with brain metastases
History of allergic or other adverse reaction to gabapentin
Intervention: Naltrexone
Trial phase: Phase 1 | Phase 2
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: 1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days
Eligibility criteria:
Inclusion Criteria:

18-65 years of age
Type 1 diabetes
Hypoglycemia unawareness
Capable of providing informed consent

Exclusion Criteria:

Concomitant regular use of acetaminophen, aspirin or ibuprofen
History of drug or alcohol abuse
Psychiatric illness
Elevations in ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), creatinine or history of hepatitis, liver failure, or renal failure/insufficiency
Pregnant or breastfeeding
Intervention: Reserpine
Trial phase: Phase 3
ATC code: C02AA02 | C02AA52 | C02LA01 | C02LA51 | C02LA71
SMILES: [H][C@]12C[C@@H](OC(=O)c3cc(OC)c(OC)c(OC)c3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@]1([H])c3[nH]c4cc(OC)ccc4c3CCN1C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 269
Group description: Test product that contains the active pharmaceutical ingredient

Tacrolimus Ointment 0.1% test product applied twice daily for 2 weeks
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of Atopic Dermatitis
Good health with the exception of Atopic Dermatitis
Percent Body Surface Area minimum requirements

Exclusion Criteria:

Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.
Subjects who have any systemic or dermatological disorders with the exception of Atopic Dermatitis